| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.05 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.05 |
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | -0.062 | 0.05 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.05 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.065 | 0.05 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.061 | 0.05 |
| mRNA | Sunitinib | CTRPv2 | pan-cancer | AAC | -0.066 | 0.05 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | -0.062 | 0.05 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.063 | 0.05 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | 0.066 | 0.05 |